Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of twice-daily inhaled doses of GSK233705B formulated with the excipient Magnesium Stearate in COPD subjects for 7-days.
darotropium bromide
AC2108378
NCT00453479
Pulmonary Disease, Chronic Obstructive
Phase 2
 
May 2013

Powered by ideaPoint, Inc.